US biotech firm Gilead Science’s (Nasdaq: GILD) combination drug Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg; previously known as the “Quad pill”) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.
Forecasts from the firm’s latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a compound annual growth rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.
As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva (efavirenz) and Reyataz (atazanavir) - both produced by Bristol-Myers Squibb - in 2014 and 2017 respectively, a more modest increase is predicted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze